Eli Lilly and Company Canadian Depositary Receipt logo

Eli Lilly and Company Canadian Depositary Receipt (LLY1)

Market Closed
17 Jul, 20:00
XFRA XFRA
7. 45
+0.1
+1.3605%
6.29B Market Cap
104.2 P/E Ratio
0.05% Div Yield
70 Volume
6.64 Eps
7.35
Previous Close
Add Transaction
Day Range
7.45 7.45
Year Range
5.45 8.2
Want to track LLY1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LLY1 closed yesterday higher at €7.45, an increase of 1.3605% from Thursday's close, completing a monthly decrease of -6.875% or -€0.55. Over the past 12 months, LLY1 stock gained 7.971%.
LLY1 pays dividends to its shareholders, with the most recent payment made on May 22, 2026.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

LLY1 Chart

People also search for

HLE
HELLA GmbH & Co. KGaA
71.3
+1.1348%
UnitedHealth Group Incorporated Canadian Depositary Receipt
7.3
-7.5949%
G0F
Grifols S.A. Sponsored ADR
4.28
+1.4218%
BUW
Bio-Rad Laboratories Inc.
232
+0.8696%
Grifols SA PRF Perpetual EUR 0.05 - Class B
6.17
0%

Eli Lilly and Company Canadian Depositary Receipt (LLY1) FAQ

What is the stock price today?

The current price is €7.45.

On which exchange is it traded?

Eli Lilly and Company Canadian Depositary Receipt is listed on XFRA.

What is its stock symbol?

The ticker symbol is LLY1.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.05%.

What is its market cap?

As of today, the market cap is 6.29B.

Has Eli Lilly and Company Canadian Depositary Receipt ever had a stock split?

No, there has never been a stock split.

Eli Lilly and Company Canadian Depositary Receipt Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. David A. Ricks CEO
XFRA Exchange
- ISIN
BR Country
50,000 Employees
- Last Dividend
- Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285
Phone: 317 276 2000